By Aakash B and Tamara Mathias (Reuters) - Eli Lilly and Co's diabetes drug Trulicity helped power higher-than-expected third-quarter profit on Tuesday, while sales of some other newer treatments fell short of Wall Street estimates.
from Latest News Business on Firstpost https://ift.tt/2yV77Cj
via IFTTT
Wednesday, November 7, 2018
Trulicity leads mixed third quarter for Lilly; shares sink
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment